LMNGF - BioVaxys's COVID-19 vaccine shows encouraging action in preclinical study

BioVaxys Technology ([[LMNGF]]) has reported interim data from preclinical clinical studies of its SARS-CoV-2 vaccine candidate, BXV-0320.The study showed that after five weeks of BVX-0320 in the murine animal model, no side effects were observed.The company anticipates taking further steps to pursue regulatory approval for a Phase I study of BVX-0320.BioVaxys's product pipeline includes BVX-0918A, an IND-stage haptenized cancer cell vaccine for late stage ovarian cancer.

For further details see:

BioVaxys's COVID-19 vaccine shows encouraging action in preclinical study